Host Species:	Goat
Concentration:	1 mg/ml (OD 1.35 / 280 nm)
Antigen:	Human Apolipoprotein CII
Purification:	Affinity purified
Buffer:	75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2
Specificity	Specifically binds to human apo CII. Dilution for immunoblot and ELISA range: 1,000 to 8,000.
Use:	The antibody can be used for detection of apo CII in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

 

Importance

Apo CII contains 78 amino acid residues. The m.w. is 8.5 kDa (Jackson et al., 1977).

The lipid-binding domain of Apo CII is localized to a region in the N-terminal with a strongly amphipathic nature (Macphee et al., 1999). Apo CII is also one of the key components of the metabolism of total triacylglycerol-rich lipoproteins by activating lipoprotein lipase that hydrolyzes fatty acids from triacylglycerols in chylomicrons (Kei et al., 2012).

Jackson, R. L., h. N. Baker, E. B. Gilliam, and A. M. Jr. Gotto. “Primary structure of very low density apolipoprotein C-II of human plasma.” Proc Natl. Acad. Sci. USA 74.5 (1977): 1942-5.

Kei, Anastazia A., Theodosios D. Filippatos, Vasilios Tsimihodimos, and Moses S. Elisaf. "A Review of the Role of Apolipoprotein C-II in Lipoprotein Metabolism and Cardiovascular Disease." Metabolism 61.7 (2012): 906-21.

Macphee, Cait E., Geoffrey J. Howlett, William H. Sawyer, and Andrew H. A. Clayton. "Helix−Helix Association of a Lipid-Bound Amphipathic α-Helix Derived from Apolipoprotein C-II." Biochemistry 38.33 (1999): 10878-0884.

 

Citations

[A10][A11]	2017	Wassef, Hanny; Bissonnette, Simon; Dufour, Robert; Davignon, Jean; Faraj, May (2017): Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. In J. Nutr. 147 (5), pp. 754–762. DOI: 10.3945/jn.116.242750.
[A10][A11]	2015	Trenchevska, Olgica; Schaab, Matthew R.; Nelson, Randall W.; Nedelkov, Dobrin (2015): Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. In Methods (San Diego, Calif.) 81, pp. 86–92. DOI: 10.1016/j.ymeth.2015.02.020.
[A10][A11]	2015	Yassine, Hussein N.; Trenchevska, Olgica; Ramrakhiani, Ambika; Parekh, Aarushi; Koska, Juraj; Walker, Ryan W. et al. (2015): The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. In PLoS ONE 10 (12), e0144138. DOI: 10.1371/journal.pone.0144138.
[A10][A11]	2006	Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743.
[A10][A11]	2005	Nedelkov, Dobrin; Kiernan, Urban A.; Niederkofler, Eric E.; Tubbs, Kemmons A.; Nelson, Randall W. (2005): Investigating diversity in human plasma proteins. In Proc Natl Acad Sci USA 102 (31), pp. 10852–10857. DOI: 10.1073/pnas.0500426102.
[A10][A11]	2001	Deeg, M. A.; Bierman, E. L.; Cheung, M. C. (2001): GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex. In J. Lipid Res. 42 (3), pp. 442–451.

 

academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种： 羊浓度： 1毫克/毫升（OD 1.35 / 280 nm）抗原： 人类载脂蛋白AII纯化： 亲和纯化缓冲： 75 mM磷酸钠，75 mM NaCl，0.5 mM EDTA，0.02％NaN3，pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围：1,000至80,000。用： 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII，免疫测定，免疫印迹，酶结合或生物素化。存储： -20°C长期保存，4°C短期保存。等分试样，以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途，不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，一项大型的欧洲前瞻性研究中的病例对照研究表明，血浆Apo AII浓度与冠心病事件密切相关（Birjmohun等，2007）。Birjmohun，RS，GM Dallinga-Thie，JA Kuivenhoven，ESg Stroes，JD Otvos，NJ Wareham，R.Luben，JJp Kastelein，K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116（2007）：2029-035。Brewer，HB，SE Lux，R.Ronan和KM John。“人ApoLp-Gln-II（apoA-II），一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5（1972）：1304-308。Warden，C.，C.Hedrick，J.Qiao，L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261（1993）：469-72。